The journal Circulation retracted a 2012 article in which its editor-in-chief is a senior author, citing compromised data.

March 27, 2014—Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically investigated the effects of the dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin on rates of CV mortality and hospitalization for heart failure (HF).

Patients who receive clonidine during noncardiac surgery may have an increased risk of hypotension and nonfatal cardiac arrest, according to research presented March 31 at the American College of Cardiology (ACC) scientific session in Washington, D.C.

Cardiac resynchronization therapy with a defibrillator (CRT-D) in patients with mild heart failure symptoms, left ventricular dysfunction and a left bundle branch block may improve survival, researchers found. They presented their late-breaking clinical trial data March 30 at the American College of Cardiology (ACC) scientific session in Washington, D.C. 

Can treating depression in patients with heart failure help them live longer? That's one of the questions that University of Pittsburgh researchers hope to answer with a new five-year, $7.3 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH).

“Today, we’re going to make history,” said 18-year-old Eric Ramos on the day UT Southwestern Medical Center doctors operated on his ailing heart. Eric, who has Duchenne muscular dystrophy, is one of only three patients in the United States with the condition to receive a battery-operated left ventricular assist device (LVAD) to keep his weakening heart pumping blood through his body. He is the first patient in the country to be given a specific, smaller LVAD, which means doctors would not need to manipulate his diaphragm, which could compromise his already limited pulmonary function.

“Today, we’re going to make history,” said 18-year-old Eric Ramos on the day UT Southwestern Medical Center doctors operated on his ailing heart. Eric, who has Duchenne muscular dystrophy, is one of only three patients in the United States with the condition to receive a battery-operated left ventricular assist device (LVAD) to keep his weakening heart pumping blood through his body. He is the first patient in the country to be given a specific, smaller LVAD, which means doctors would not need to manipulate his diaphragm, which could compromise his already limited pulmonary function.

Can treating depression in patients with heart failure help them live longer? That's one of the questions that University of Pittsburgh researchers hope to answer with a new five-year, $7.3 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH).